Clinical trials · St. Louis, MO
Metastatic Prostate Cancer clinical trials in St. Louis
We’re tracking 51 recruiting metastatic prostate cancer studies with a site in or near St. Louis — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near St. Louis
- NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
St Louis, MissouriAges 18 years+ - NCT06470243RecruitingPhase 3
Adding carboplatin to cabazitaxel for advanced prostate cancer
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
St Louis, MissouriAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
St Louis, MissouriAges 18 years+ - NCT05939414RecruitingPhase 3
Study of radioactive drug for prostate cancer that has spread a little
This study tests a radioactive drug (177Lu-PSMA-617) compared to no immediate treatment in men with prostate cancer that has returned and spread to a few spots (oligometastatic). It aims to see if this treatment delays the spread of cancer and improves outcomes.
St Louis, MissouriAges 18–100 - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
St Louis, MissouriAges 18 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
St Louis, MissouriAges 18 years+ - NCT04868604RecruitingPhase 1/Phase 2
Copper PSMA scan and treatment for prostate cancer in men on low testosterone
This trial tests a PSMA-targeted copper medicine used after a special PSMA PET/CT scan to find and treat prostate cancer that has spread. It’s for men whose testosterone is already very low and whose cancer is growing despite hormone-blocking medicines like enzalutamide or abiraterone.
St Louis, MissouriAges 18 years+ - NCT07200830RecruitingPhase 3
Testing different schedules of a targeted radiation drug for advanced prostate cancer
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
St Louis, MissouriAges 18 years+ - NCT05818683RecruitingPhase 1
Pasritamig plus other drugs for advanced prostate cancer
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
St Louis, MissouriAges 18 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
St Louis, MissouriAges 18 years+ - NCT07221825Recruiting
Radium-223 imaging study for men with prostate cancer
This study uses a special type of scan (quantitative SPECT) to measure how Radium-223 (Xofigo) works in your bones. It helps doctors better understand treatment for prostate cancer that has spread to the bones.
St Louis, MissouriAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
St Louis, MissouriAges Any age - NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
St Louis, MissouriAges 18 years+ - NCT03821246RecruitingPhase 2
Atezolizumab and other drugs before prostate surgery for high-risk cancer
This Phase 2 trial tests whether giving immunotherapy (atezolizumab) plus another drug before surgery can shrink or control high-risk localized prostate cancer. The goal is to improve outcomes by treating the cancer early, before radical prostatectomy.
St Louis, MissouriAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
St Louis, MissouriAges 18 years+ - NCT05058651RecruitingPhase 2/Phase 3
Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
St Louis, MissouriAges 18 years+ - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
St Louis, MissouriAges 18 years+ - NCT06465069RecruitingPhase 1
Study of an experimental drug for advanced bladder and other cancers
This trial tests a new drug called LY4052031 for people with advanced or metastatic cancers, especially bladder cancer. The drug aims to slow or stop tumor growth. Doctors will check if it is safe and how well it works.
St Louis, MissouriAges 18 years+ - NCT06134232RecruitingPhase 2
Extra sipuleucel-T after Provenge for prostate cancer
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
St Louis, MissouriAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
St Louis, MissouriAges 18 years+ - NCT07569926RecruitingPhase 4
Fluciclovine PET scan for prostate cancer recurrence detection
This study tests whether a newer type of imaging scan (called fluciclovine PET) can find where prostate cancer has come back when an earlier scan (PSMA PET) didn't show clear results. The goal is to help doctors better plan treatment for men whose cancer has returned after surgery or radiation.
St Louis, MissouriAges 18 years+ - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
St Louis, MissouriAges 18–100 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
St Louis, MissouriAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
St Louis, MissouriAges 18 years+
Hear when a new Metastatic Prostate Cancer trial opens near St. Louis, MO
We’ll email you when one opens near St. Louis, MO — at most once a week, no account needed, unsubscribe anytime.
Metastatic Prostate Cancer trials in other cities
Where these studies are running near St. Louis
Institutions with a site for the recruiting metastatic prostate cancer studies listed above.
- Washington University in St. Louis · 11 studies
- Cancer Care Center of O'Fallon · 6 studies
- Mercy Hospital South · 5 studies
- Missouri Baptist Medical Center · 5 studies
- Siteman Cancer Center · 5 studies
- Sainte Genevieve County Memorial Hospital · 4 studies
- Siteman Cancer Center at Saint Peters Hospital · 4 studies
- Siteman Cancer Center at West County Hospital · 4 studies
What taking part in a metastatic prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic prostate cancer studies in Missouri.
Common questions
- Are there metastatic prostate cancer clinical trials near St. Louis?
- Yes. We're currently tracking 51 recruiting metastatic prostate cancer studies with a site near St. Louis, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic prostate cancer study near St. Louis?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in St. Louis to take part?
- Not necessarily. These studies have a site near St. Louis, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic prostate cancer studies open near St. Louis regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.